Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

NCT06334432 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT06334432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06334432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 14, 2024
Completion date
October 31, 2027
Enrollment
466 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, her2-negative breast cancer, metastatic castration-resistant prostate cancer (mcrpc), pancreatic cancer, platinum-resistant ovarian cancer (proc)